RxDoctor Payments Data

Richard Link, MD

Internal Medicine · Brooklyn, NYNPI 1730114547

Payments from drug & device makers

$1,220in general payments, 2019–2025

Across 52 payments — averaging $23.45 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Lilly USA, LLC$275
  • AstraZeneca$189
  • AbbVie$134
  • Gilead$88
  • Pfizer$71
  • Exact Sciences$68
  • plus $395 from 11 others

What the payments were for

  • Food & beverage$1,220100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,220 in reported general payments places this provider in the 70th percentile of 9,771 internal medicine providers in New York.

See all internal medicine providers in New York

Medicare billing

Part B allowed, 2024
$82,876
Medicare patients
80
Services billed
994

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol41$33,221
DescovyEmtricitabine/Tenofov Alafenam15$29,216
JanuviaSitagliptin Phosphate28$26,345
JardianceEmpagliflozin44$21,316
TradjentaLinagliptin22$21,019
EliquisApixaban24$18,810
OzempicSemaglutide20$18,396
MounjaroTirzepatide16$16,111
Advair HfaFluticasone Propion/Salmeterol21$7,496
Spiriva HandihalerTiotropium Bromide12$6,184
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr12$5,407
Lantus SolostarInsulin Glargine,hum.Rec.Anlog33$4,291
Clobetasol Propionate47$3,675
Albuterol Sulfate HfaAlbuterol Sulfate143$3,516
Advocate Pen NeedlesPen Needle, Diabetic24$2,696

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$189$33,22141 claims
GileadDescovy$88$29,21615 claims
Novo NordiskOzempic, Levemir$48$20,31139 claims
PfizerEliquis$71$18,81024 claims
Lilly USA, LLCMounjaro$275$16,11116 claims
GSKAnoro Ellipta$30$5,40712 claims
AbbVieSynthroid$134$1,37017 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 9,771 internal medicine providers in New York.

Other internal medicine in Brooklyn

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →